Compare · QDEL vs TKNO
QDEL vs TKNO
Side-by-side comparison of QuidelOrtho Corporation (QDEL) and Alpha Teknova Inc. (TKNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both QDEL and TKNO operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- QDEL is the larger of the two at $789.1M, about 4.6x TKNO ($170.5M).
- Over the past year, QDEL is down 60.0% and TKNO is down 52.5% - TKNO leads by 7.6 points.
- QDEL has been more active in the news (9 items in the past 4 weeks vs 3 for TKNO).
- QDEL has more recent analyst coverage (18 ratings vs 7 for TKNO).
- Company
- QuidelOrtho Corporation
- Alpha Teknova Inc.
- Price
- -
- -
- Market cap
- $789.1M
- $170.5M
- 1M return
- -27.67%
- +4.59%
- 1Y return
- -60.03%
- -52.46%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 9
- 3
- Recent ratings
- 18
- 7
QuidelOrtho Corporation
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, it offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, the company provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers Lyra molecular real-time polymerase chain reaction assays; Solana, an amplification and detection system; and Virena, a wireless cellular data management and surveillance system The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was incorporated in 1979 and is headquartered in San Diego, California.
Latest QDEL
- Chief Operations Officer Mclellan Philip D. was granted 3,238 shares and covered exercise/tax liability with 1,162 shares, increasing direct ownership by 11% to 21,250 units (SEC Form 4) (for tax liability)
- EVP Global Port. Mgmt & Mkting Hanson Bryan Michael was granted 3,508 shares and covered exercise/tax liability with 1,269 shares, increasing direct ownership by 249% to 3,139 units (SEC Form 4) to cover taxes
- Understanding and Addressing Syphilis Trends - and What's Being Missed
- SEC Form 4 filed by Sisitsky Nathaniel
- TTP Group Announces the Sale of LEX Diagnostics
- QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics
- QuidelOrtho Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- QuidelOrtho Announces Preliminary Revenue for the First Quarter 2026 and Provides Update on Full-Year 2026 Guidance
- Amendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho Corporation
- SEC Form 3 filed by new insider Sisitsky Nathaniel
Latest TKNO
- Teknova to Report First Quarter 2026 Financial Results on May 6, 2026
- SEC Form DEFA14A filed by Alpha Teknova Inc.
- SEC Form DEF 14A filed by Alpha Teknova Inc.
- SEC Form 4 filed by General Counsel and CCO Terrill Damon
- Chief Financial Officer Lowell Matthew bought $87,616 worth of shares (40,000 units at $2.19), increasing direct ownership by 31% to 168,376 units (SEC Form 4)
- President and CEO Gunstream Stephen bought $55,801 worth of shares (26,000 units at $2.15), increasing direct ownership by 11% to 269,497 units (SEC Form 4)
- SEC Form 10-K filed by Alpha Teknova Inc.
- Alpha Teknova Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Teknova Reports Fourth Quarter and Full Year 2025 Financial Results
- Teknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026